These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11438029)

  • 1. Preparation of lyophilized and liquid intravenous immunoglobulin G: development and scale-up.
    Sisti AM; Vitali MS; Manfredi MJ; Zarzur JA
    Vox Sang; 2001 May; 80(4):216-24. PubMed ID: 11438029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency.
    Kallenberg CG
    Clin Exp Immunol; 2007 Dec; 150(3):437-41. PubMed ID: 17956584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.
    Mahieu AC; Sisti AM; Joekes S; Manfredi MJ
    Allergol Immunopathol (Madr); 2006; 34(6):242-7. PubMed ID: 17173840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High quality human immunoglobulin G purified from Cohn fractions by liquid chromatography.
    Tanaka K; Sawatani E; Dias GA; Shigueoka EM; Campos TC; Nakao HC; Arashiro F
    Braz J Med Biol Res; 2000 Jan; 33(1):27-30. PubMed ID: 10625871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Isoagglutinin in Intravenous Immunoglobulin (IVIG) Using Blood Group A- and B-Specific Immunoaffinity Chromatography: Industry-Scale Assessment.
    Gerber S; Gaida A; Spiegl N; Wymann S; Antunes AM; Menyawi IE; Zurbriggen B; Hubsch A; Imboden M
    BioDrugs; 2016 Oct; 30(5):441-451. PubMed ID: 27646589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc function of a new intravenous immunoglobulin product: IGIV 10% triple virally inactivated solution.
    Reipert BM; Ilas J; Carnewal C; Füreder SF; Bölzlbauer U; Teschner W; Fiedler C; Schwarz HP
    Vox Sang; 2006 Oct; 91(3):256-63. PubMed ID: 16958839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation, purification and virus inactivation of intravenous immunoglobulin from human plasma.
    Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Banazadeh S
    Hum Antibodies; 2010; 19(1):1-6. PubMed ID: 20555125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.
    Wolf HH; Davies SV; Borte M; Caulier MT; Williams PE; Bernuth HV; Egner W; Sklenar I; Adams C; Späth P; Morell A; Andresen I
    Vox Sang; 2003 Jan; 84(1):45-53. PubMed ID: 12542733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A chromatographic method for the production of a human immunoglobulin G solution for intravenous use.
    Tanaka K; Sawatani E; Shigueoka EM; Campos TC; Nakao HC; Dias GA; Fujita RK; Arashiro F
    Braz J Med Biol Res; 1998 Nov; 31(11):1375-81. PubMed ID: 9921271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
    Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
    Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin G dimers and immune complexes are dispensable for the therapeutic efficacy of intravenous immune globulin in murine immune thrombocytopenia.
    Tremblay T; Paré I; Bazin R
    Transfusion; 2013 Feb; 53(2):261-9. PubMed ID: 22670706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro evaluation of the biological activities of IgG in seven Chinese intravenous immunoglobulin preparations.
    Ye S; Li D; Liu F; Lei M; Jiang P; Wang Z; Zhang R; Du X; Cao H; Ma L; Li C
    J Pharm Biomed Anal; 2018 Mar; 151():317-323. PubMed ID: 29413980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticomplementary activity of IVIG concentrates--important assay parameters and impact of IgG polymers.
    Buchacher A; Schluga P; Müllner J; Schreiner M; Kannicht C; Weinberger J
    Vox Sang; 2010 Apr; 98(3 Pt 1):e209-18. PubMed ID: 20432511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.
    Kreil TR; Mc Vey JK; Lei LS; Camacho L; Wodal W; Kerschbaum A; Segura E; Vandamme E; Gavit P; Ehrlich HJ; Barrett PN; Baker DA
    Transfusion; 2012 Apr; 52(4):803-9. PubMed ID: 21981280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
    Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
    Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. International collaborative study to evaluate a candidate reference preparation to define an appropriate specified limit of anti-D in intravenous immunoglobulin products.
    Thorpe SJ; Fox B; Heath A; Dolman C; Virata ML; Yu MW; Thorpe R
    Vox Sang; 2005 May; 88(4):278-87. PubMed ID: 15877651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Requirements for safety and quality of intravenous immunoglobulin G preparations.
    Rütter GH
    J Neurol Neurosurg Psychiatry; 1994 Nov; 57 Suppl(Suppl):2-5. PubMed ID: 7964845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of two intravenous immunoglobulin. Preparations for immunoglobulin G subclasses and specific antibodies to bacterial surface antigens and relation with their levels in treated immunodeficient patients.
    Lamari F; Karamanos NK; Papadopoulou-Alataki E; Kanakoudi-Tsakalidou F; Dimitracopoulos G; Anastassiou ED
    J Pharm Biomed Anal; 2000 Jul; 22(6):1029-36. PubMed ID: 10857572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravenous immunoglobulin therapy].
    Mouthon L
    Rev Prat; 2005 May; 55(10):1049-56. PubMed ID: 16097244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.